Biotech
Emerging and mid-cap biopharma firms, often venture-backed and focused on advancing new platforms and modalities
A clear perspective onthe science, strategy and capital allocation
We advise biotech management teams and investors on the decisions that matter most. Our work spans asset positioning, out-licensing and partnering, commercial due diligence, and transaction support. We benchmark valuations against comparable deals, analyse competitor pipelines and therapeutic landscapes, and assess partnership options that balance near-term funding with long-term growth potential.
Our biotech leads
Our teams combine scientific expertise with deal experience. We bring rigour to forecasting and valuation, assess regulatory and market access dynamics, and help frame development strategies that appeal to potential partners or acquirers. This ensures that investment cases are built on realistic assumptions and that transactions are structured to capture fair value.
Beyond transactions, we support operational priorities such as target operating model design, performance improvement, and digital and data strategy. By combining strategic clarity with an understanding of scientific and clinical realities, we help biotech firms and their backers make sound decisions in an increasingly competitive market.
News & Insights
